여성건강진단 시장 규모, 점유율, 동향 분석 리포트 : 용도별, 최종 용도별, 지역별(2025-2030년)

Women´s Health Diagnostics Market Size, Share, & Trends Analysis Report By Application (Cancer, Infectious Disease, Osteoporosis), By End Use (Hospitals, Laboratory, Home Care), By Region, 2025 - 2030

US $ 5,950 ￦ 8,605,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,051,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,944,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

여성건강진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 여성건강진단 시장 규모는 2030년까지 314억 6,000만 달러에 달할 전망입니다.

이 시장은 2025-2030년 연평균 7.29%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다. POC(Point of Care) 진단의 채택 증가, 다양한 만성질환 및 생활습관병의 유병률 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 이 외에도 다양한 인식 개선 프로그램의 도입도 예측 기간 중 시장에 유리하게 작용할 것으로 예상됩니다. 예를 들어 2014년 유럽연합 집행위원회는 '종합적 암 관리의 질 향상에 대한 유럽 가이드'의 공동 활동을 시작했습니다.

여성 건강검진은 다양한 단체의 자금 지원 증가로 인해 높은 성장세를 보이고 있습니다. 예를 들어 2015년 5월 Abcodia는 난소암 조기 발견을 위한 ROCA(Risk of Ovarian Cancer Algorithm) 검사를 영국에서 출시하기 위해 Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, UCLB로부터 800만 달러 자금 제공을 받았습니다.

최종 용도별로 보면 시장은 병원 및 진단센터와 가정용으로 양분됩니다. 병원 및 진단센터는 병원 방문 횟수가 많고, 보다 확실한 검출이 가능하므로 시장에서 큰 비중을 차지하고 있습니다.

아시아태평양 시장은 향후 수년간 크게 성장할 가능성이 높습니다. 이 시장의 성장은 헬스케어에 대한 투자 증가, 국제적인 의료기기 제조업체들이 이 지역의 판매망 강화에 주력하고 있으며, 지역내 감염성 질환에서 만성질환으로 역학이 전환되고 있기 때문입니다.

여성 건강검진 시장 보고서 하이라이트

• 정부 및 민간단체의 투자 증가와 가처분 소득 증가가 시장을 촉진하고 있습니다.
• 2024년 시장 점유율은 암이 가장 높을 것으로 예상됩니다. 이 분야는 조기 발견 검사의 가용성과 암에 대한 정부의 구상으로 인해 예측 기간 중 주목할 만한 성장을 기록할 것으로 보입니다.
• 산전 검사는 산전 질환의 유병률 증가, 산모 연령 증가, 의료비 지출 급증, 첨단 진단 검사의 개발로 인해 같은 기간 중 가장 빠르게 성장하는 분야로 추정됩니다.
• 지역별로는 북미가 2024년 46.21%의 최대 매출 점유율을 차지하며 시장을 장악했습니다. 진단센터 및 영상 진단센터 기반 확대, 암 환자 증가, 불임 검사에 대한 인식 증가, POC(Point-Of-Care) 검사 장비의 보급 등으로 인해 2030년까지 그 우위를 유지할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 여성건강진단 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장의 전망
• 시장 역학
  • 시장 드라이버 분석
  • 시장 성장 억제요인 분석
• 여성건강진단 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 여성건강진단 시장 : 부문 분석, 애플리케이션별, 2018-2030년(백만 달러)

• 정의와 범위
• 애플리케이션 시장 점유율 분석, 2024년 및 2030년
• 여성건강진단 시장, 용도별, 2018-2030년
• 시장 규모와 예측 및 동향 분석, 2018-2030년

제5장 여성건강진단 시장 : 부문 분석, 최종 용도별, 2018-2030년(백만 달러)

• 정의와 범위
• 최종 용도 시장 점유율 분석, 2024년 및 2030년
• 세계의 여성건강진단 시장, 최종 용도별, 2018-2030년
• 시장 규모와 예측 및 동향 분석, 2018-2030년

제6장 여성건강진단 시장 : 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 태국
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 시장 참여 기업의 분류
• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업 시장 점유율 분석, 2024년
• 주요 기업 개요
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Quest Diagnostics Incorporated
  • Abbott
  • BD
  • GE Healthcare
  • Koninklijke Philips NV
  • Aspira Women's Health
  • Thermo Fisher Scientific Inc.
  • Cardinal Health, Inc.

KSA

영문 목차

영문목차

Women's Health Diagnostics Market Growth & Trends:

The global women's health diagnostics market size is expected to reach USD 31.46 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.29% from 2025 to 2030. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.

Women's health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.

On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.

The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.

Women's Health Diagnostics Market Report Highlights:

• Increasing investments by governments and private bodies and rising disposable income are providing a push to the market
• Cancer accounted for the highest share in the market in 2024. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer
• Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests
• Geographically, North America dominated the market and accounted for the largest revenue share of 46.21% in 2024. It is anticipated to maintain its dominance through 2030, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Women's Health Diagnostics Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of various health conditions in women
    • 3.2.1.2. Growing women health awareness,
    • 3.2.1.3. Technological advancements in diagnostics equipment
    • 3.2.1.4. Aging women population
    • 3.2.1.5. Developing global healthcare infrastructure
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of access of diagnostic solutions
    • 3.2.2.2. High cost of diagnostic solutions
• 3.3. Women's Health Diagnostics Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Women's Health Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 4.1. Definition and Scope
• 4.2. Application Market Share Analysis, 2024 & 2030
• 4.3. Women's Health Diagnostics Market, by Application, 2018 to 2030
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 4.4.1. Cancer
    • 4.4.1.1. Cancer market, 2018 - 2030 (USD Million)
  • 4.4.2. Infectious diseases
    • 4.4.2.1. Infectious diseases market, 2018 - 2030 (USD Million)
  • 4.4.3. Osteoporosis
    • 4.4.3.1. Osteoporosis market, 2018 - 2030 (USD Million)
  • 4.4.4. Pregnancy & fertility
    • 4.4.4.1. Pregnancy & fertility market, 2018 - 2030 (USD Million)
  • 4.4.5. Prenatal
    • 4.4.5.1. Prenatal market, 2018 - 2030 (USD Million)

Chapter 5. Women's Health Diagnostics Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 5.1. Definition and Scope
• 5.2. End Use Market Share Analysis, 2024 & 2030
• 5.3. Global Women's Health Diagnostics Market, by End Use, 2018 to 2030
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1. Hospitals
    • 5.4.1.1. Hospitals market, 2018 - 2030 (USD Million)
  • 5.4.2. Laboratory
    • 5.4.2.1. Laboratory market, 2018 - 2030 (USD Million)
  • 5.4.3. Home care
    • 5.4.3.1. Home care market, 2018 - 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Women's Health Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. China
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. South Africa
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Saudi Arabia
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. UAE
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Kuwait
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Key Company Profiles
  • 7.4.1. F. Hoffmann-La Roche Ltd.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Hologic, Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Quest Diagnostics Incorporated
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Abbott
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. BD
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. GE Healthcare
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Koninklijke Philips N.V.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Aspira Women's Health
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Thermo Fisher Scientific Inc.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Cardinal Health, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives

관련자료